FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039982019> ?p ?o ?g. }

• W2039982019 endingPage "1837" @default.
• W2039982019 startingPage "1837" @default.
• W2039982019 abstract "Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients.To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain.Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997.Sixteen US outpatient clinical centers.A total of 229 subjects were randomized.A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study.The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0, no pain; 10, worst possible pain) from baseline week to the final week of therapy. Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF-36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events.One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 received placebo, and 95 (81.9%) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P<.001). Secondary measures of pain as well as changes in pain and sleep interference showed improvement with gabapentin (P<.001). Many measures within the SF-36 and POMS also significantly favored gabapentin (P< or =.01). Somnolence, dizziness, ataxia, peripheral edema, and infection were all more frequent in the gabapentin group, but withdrawals were comparable in the 2 groups (15 [13.3%] in the gabapentin group vs 11 [9.5%] in the placebo group).Gabapentin is effective in the treatment of pain and sleep interference associated with PHN. Mood and quality of life also improve with gabapentin therapy." @default.
• W2039982019 created "2016-06-24" @default.
• W2039982019 creator A5042683460 @default.
• W2039982019 creator A5049491343 @default.
• W2039982019 creator A5052440672 @default.
• W2039982019 creator A5063692169 @default.
• W2039982019 creator A5080218957 @default.
• W2039982019 date "1998-12-02" @default.
• W2039982019 modified "2023-10-10" @default.
• W2039982019 title "Gabapentin for the Treatment of Postherpetic Neuralgia<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>" @default.
• W2039982019 cites W1964941904 @default.
• W2039982019 cites W1966476039 @default.
• W2039982019 cites W1982022301 @default.
• W2039982019 cites W1991353203 @default.
• W2039982019 cites W2013521922 @default.
• W2039982019 cites W2032998637 @default.
• W2039982019 cites W2033573454 @default.
• W2039982019 cites W2033809334 @default.
• W2039982019 cites W2057088834 @default.
• W2039982019 cites W2060880376 @default.
• W2039982019 cites W2071709883 @default.
• W2039982019 cites W2081887464 @default.
• W2039982019 cites W2085160334 @default.
• W2039982019 cites W2088725132 @default.
• W2039982019 cites W2117838151 @default.
• W2039982019 cites W2118649138 @default.
• W2039982019 cites W2136568920 @default.
• W2039982019 cites W2144504916 @default.
• W2039982019 cites W2150883260 @default.
• W2039982019 cites W2322450883 @default.
• W2039982019 cites W2329029822 @default.
• W2039982019 cites W2409364977 @default.
• W2039982019 cites W2507393820 @default.
• W2039982019 cites W2588572157 @default.
• W2039982019 cites W27476833 @default.
• W2039982019 cites W148112286 @default.
• W2039982019 cites W2123741978 @default.
• W2039982019 cites W2496442096 @default.
• W2039982019 doi "https://doi.org/10.1001/jama.280.21.1837" @default.
• W2039982019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9846778" @default.
• W2039982019 hasPublicationYear "1998" @default.
• W2039982019 type Work @default.
• W2039982019 sameAs 2039982019 @default.
• W2039982019 citedByCount "1377" @default.
• W2039982019 countsByYear W20399820192012 @default.
• W2039982019 countsByYear W20399820192013 @default.
• W2039982019 countsByYear W20399820192014 @default.
• W2039982019 countsByYear W20399820192015 @default.
• W2039982019 countsByYear W20399820192016 @default.
• W2039982019 countsByYear W20399820192017 @default.
• W2039982019 countsByYear W20399820192018 @default.
• W2039982019 countsByYear W20399820192019 @default.
• W2039982019 countsByYear W20399820192020 @default.
• W2039982019 countsByYear W20399820192021 @default.
• W2039982019 countsByYear W20399820192022 @default.
• W2039982019 countsByYear W20399820192023 @default.
• W2039982019 crossrefType "journal-article" @default.
• W2039982019 hasAuthorship W2039982019A5042683460 @default.
• W2039982019 hasAuthorship W2039982019A5049491343 @default.
• W2039982019 hasAuthorship W2039982019A5052440672 @default.
• W2039982019 hasAuthorship W2039982019A5063692169 @default.
• W2039982019 hasAuthorship W2039982019A5080218957 @default.
• W2039982019 hasBestOaLocation W20399820191 @default.
• W2039982019 hasConcept C126322002 @default.
• W2039982019 hasConcept C142724271 @default.
• W2039982019 hasConcept C168563851 @default.
• W2039982019 hasConcept C1862650 @default.
• W2039982019 hasConcept C197934379 @default.
• W2039982019 hasConcept C204787440 @default.
• W2039982019 hasConcept C27081682 @default.
• W2039982019 hasConcept C2776000289 @default.
• W2039982019 hasConcept C2776608144 @default.
• W2039982019 hasConcept C2777107010 @default.
• W2039982019 hasConcept C2778866549 @default.
• W2039982019 hasConcept C42219234 @default.
• W2039982019 hasConcept C71924100 @default.
• W2039982019 hasConceptScore W2039982019C126322002 @default.
• W2039982019 hasConceptScore W2039982019C142724271 @default.
• W2039982019 hasConceptScore W2039982019C168563851 @default.
• W2039982019 hasConceptScore W2039982019C1862650 @default.
• W2039982019 hasConceptScore W2039982019C197934379 @default.
• W2039982019 hasConceptScore W2039982019C204787440 @default.
• W2039982019 hasConceptScore W2039982019C27081682 @default.
• W2039982019 hasConceptScore W2039982019C2776000289 @default.
• W2039982019 hasConceptScore W2039982019C2776608144 @default.
• W2039982019 hasConceptScore W2039982019C2777107010 @default.
• W2039982019 hasConceptScore W2039982019C2778866549 @default.
• W2039982019 hasConceptScore W2039982019C42219234 @default.
• W2039982019 hasConceptScore W2039982019C71924100 @default.
• W2039982019 hasIssue "21" @default.
• W2039982019 hasLocation W20399820191 @default.
• W2039982019 hasLocation W20399820192 @default.
• W2039982019 hasOpenAccess W2039982019 @default.
• W2039982019 hasPrimaryLocation W20399820191 @default.
• W2039982019 hasRelatedWork W1972762029 @default.
• W2039982019 hasRelatedWork W1988457590 @default.
• W2039982019 hasRelatedWork W2010703163 @default.
• W2039982019 hasRelatedWork W2194911575 @default.

• next